Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer

NCT ID: NCT05979298

Last Updated: 2023-08-07

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-11-15
• Study Completion Date: 2024-12-30

Brief Summary

Phase II, two arm prospective study of efficacy and safety of ELENAGEN in combination with gemcitabine in comparison with gemcitabine alone in patients with platinum-resistant ovarian cancer.

Detailed Description

The purpose of this clinical study is to evaluate safety and efficacy of ELENAGEN, a novel anticancer therapeutics (plasmid DNA encoding p62/SQSTM1) protein, as an adjuvant to chemotherapy with Gemcitabin (GEM) in patients with advanced platinum-resistant ovarian cancer.

This is a prospective randomized multi-center study with two arms. Gemcitabine 1000 mg/m2 days 1,8 every 3 weeks) is administered in both arms: In the Chemo arm (n = 20) Gemcitabine is the only treatment, and in the ELENAGEN arm (n = 20) GEM was supplemented with ELENAGEN (2.5 mg i.m. weekly). The primary endpoint is progression-free survival (PFS), and the secondary endpoint is safety.

Conditions

Ovarian Cancer; Platinum-resistant Ovarian Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Gemcitabin

Gemcitabine 1000 mg/m2 days 1,8 every 3 weeks

Group Type: ACTIVE_COMPARATOR

Gemcitabine

Intervention Type: DRUG

Chemotherapeutics

Gemcitabine+Elenagen

GEM was supplemented with ELENAGEN (2.5 mg i.m. weekly)

Group Type: EXPERIMENTAL

Gemcitabine

Intervention Type: DRUG

Chemotherapeutics

ELENAGEN

Intervention Type: BIOLOGICAL

DNA plasmid

Interventions

Gemcitabine

Chemotherapeutics

Intervention Type: DRUG

ELENAGEN

DNA plasmid

Intervention Type: BIOLOGICAL

Other Intervention Names

Gemzar

Eligibility Criteria

Inclusion Criteria

• The patient is 18-70 years old.
• Written informed consent of the patient to participate in clinical trials.
• Presence of histologically confirmed ovarian cancer.
• The return of the disease occurred less than 6 months after the last administration of platinum.
• Presence of measurable tumor lesions according to RECIST 1.1 criteria.
• Functional status according to ECOG scale is 0-2.
• Life expectancy of at least 6 months.
• Adequate function of the organs as determined by the following criteria:

1. Absolute number of neutrophils (ANN) ≥1500/mm3 (≥1.5 × 109/l);

2. Platelet count ≥100,000/mm3 (IU: ≥100 × 109/l).

3. Hemoglobin level ≥ 9.0 g/dL determined by analysis performed at least 2 weeks after the last hemotransfusion;

4. The level of AST and ALT in blood serum not exceeding more than 3 times the upper limit of the norm.

5. The level of serum bilirubin not exceeding more than 1.5 times the upper limit of normal.

6. Serum Creatinine ≤ 1.5 mg/dL.

• The ability of the patient to follow the directions of the research physician and follow the study regimen.

Exclusion Criteria

Criteria by which patients are not included in the study

• Platinum-sensitive relapse of ovarian cancer (disease recurrence occurred more than 6 months after the last administration of platinum drugs).
• Presence of serious diseases or health conditions:

1. Other malignancies, with the exception of malignancies treated more than 5 years ago without signs of return of the disease.

2. Brain metastases or leptomeningeal metastases.

3. Active infection (e.g. fever ≥38 °C), including active or unresolved pneumonia/pneumonitis.

4. Uncontrolled diabetes mellitus.

5. Myocardial Infarction in the last 12 months, severe/unstable angina, clinically manifested heart failure class III-IV according to the classification of the New York Cardiology Association (NYCA).

6. Gastrointestinal bleeding within the last 2 weeks.

7. Human immunodeficiency virus (HIV), chronic or acute hepatitis B or hepatitis C.

8. Patients with autoimmune disorders or organ transplantation who require immunosuppressive therapy.

I. Mental illness that may increase the risk associated with participation in the study or taking the study drug or that may affect the interpretation of the results of the study.

K. Polyallergy, bronchial asthma (including aspirin) in history.

• Major surgery during the previous 4 weeks (complete wound healing).
• Previous chemotherapeutic treatment of the patient according to the scheme GEMCITABINE
• Radiotherapy with extended field radiation within the previous 4 weeks or radiotherapy with a limited field radiation within the previous 2 weeks.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

CureLab Oncology

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Minsk City Clinical Oncology Center

Minsk, , Belarus

Countries

Belarus

References

Krasny S, Baranau Y, Polyakov S, Zharkova E, Streltsova O, Filimonava A, Siarheyeva V, Kazlouskaya S, Khorau A, Gabai V, Shneider A. Clinical efficacy of plasmid encoding p62/SQSTM1 (Elenagen) in combination with gemcitabine in patients with platinum-resistant ovarian cancer: a randomized controlled trial. Front Oncol. 2024 Feb 12;14:1343023. doi: 10.3389/fonc.2024.1343023. eCollection 2024.

Reference Type: DERIVED

PMID: 38410116 (View on PubMed)

Other Identifiers

PROC0319

Identifier Type: -

Identifier Source: org_study_id